Evaluation of investigator bias in industry-funded clinical trials of latanoprost.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcjo.2011.09.015PMID 22153642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins.

  2009cited by this paper
• Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.

  2008cited by this paper
• Side effects associated with prostaglandin analog therapy.

  2008cited by this paper
• Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.

  2008cited by this paper
• Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients.

  2007cited by this paper
• A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension.

  2007cited by this paper
• Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension.

  2007cited by this paper
• A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.

  2007cited by this paper
• Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.

  2007cited by this paper
• Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.

  2006cited by this paper
• A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patients*

  2006cited by this paper
• Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.

  2006cited by this paper
• Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.

  2006cited by this paper
• Bias from industry trial funding? A framework, a suggested approach, and a negative result

  2006cited by this paper
• Effect of medical therapy on glaucoma filtration surgery rates in Ontario.

  2005cited by this paper
• Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.

  2005cited by this paper
• The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%

  2005cited by this paper
• 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.

  2004cited by this paper
• The Efficacy and Safety of Once-Daily Versus Once-Weekly Latanoprost Treatment for Increased Intraocular Pressure

  2004cited by this paper
• Evaluation of the Additive Effect of Bunazosin on Latanoprost in Primary Open-Angle Glaucoma

  2004cited by this paper
• The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study

  2004cited by this paper
• Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.

  2004cited by this paper
• Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.

  2004cited by this paper
• Intraocular Pressure Fluctuations in Response to the Water-Drinking Provocative Test in Patients Using Latanoprost Versus Unoprostone

  2004cited by this paper
• Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma.

  2003cited by this paper
• A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.

  2003cited by this paper
• Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.

  2003cited by this paper
• The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.

  2003cited by this paper
• Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.

  2003cited by this paper
• Latanoprost, Bimatoprost, and Travoprost in Patients With Elevated Intraocular Pressure: Results of a 12-Week, Masked-Evaluator, Multicenter Study

  2003cited by this paper
• A Comparative Clinical Study of Latanoprost and Isopropyl Unoprostone in Japanese Patients with Primary Open-Angle Glaucoma and Ocular Hypertension

  2002cited by this paper
• Intraocular Pressure-Lowering Effects of Latanoprost and Brimonidine Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension: A Randomized Observer-Masked Multicenter Study

  2002cited by this paper
• Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.

  2002cited by this paper
• A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.

  2001cited by this paper
• Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension.

  2001cited by this paper
• A Comparison of Intraocular Pressure-Lowering Effect of Prostaglandin F2-&agr; Analogues, Latanoprost, and Unoprostone Isopropyl

  2001cited by this paper
• A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.

  2001cited by this paper
• A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.

  2001cited by this paper
• Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.

  2000cited by this paper
• A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study

  2000cited by this paper
• Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients

  2000cited by this paper
• Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.

  1999cited by this paper
• Latanoprost

  1998cited by this paper
• Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

  1998cited by this paper
• A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension

  1997cited by this paper

• Evidence for stratified conflicts of interest policies in research contexts: a methodological review

  2022cites this paper
• Industry sponsorship and research outcome.

  2017cites this paper
• Representation of Women With Industry Ties in Ophthalmology.

  2016cites this paper
• Assessment of methodologic quality of randomized trials of interventional techniques: development of an interventional pain management specific instrument.

  2014cites this paper
• Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications

  2014cites this paper